SecSonar.com

BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

BridgeBio Pharma, Inc. (BBIO) is a Biotechnology company based in US with a market capitalization of $13.2B. Revenue grew 126.3% year-over-year and free cash flow was negative at -$447M. This page tracks BBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 725 employees · IPO Jun 27, 2019

Valuation

Valuation & price

$66.13 · as of May 17, 2026 · -17.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$79.10$61.30$43.50Jul 25Dec 25Jul 26Jul 7, 25$43.50Jul 9, 25$45.98Jul 11, 25$46.47Jul 15, 25$46.97Jul 17, 25$46.74Jul 21, 25$45.90Jul 23, 25$46.19Jul 25, 25$46.30Jul 29, 25$46.32Jul 31, 25$47.27Aug 4, 25$47.75Aug 6, 25$44.81Aug 11, 25$48.24Aug 13, 25$50.38Aug 15, 25$51.32Aug 19, 25$48.91Aug 21, 25$50.23Aug 25, 25$47.29Aug 27, 25$49.59Aug 29, 25$51.76Sep 3, 25$51.84Sep 5, 25$53.38Sep 9, 25$53.50Sep 11, 25$52.60Sep 16, 25$51.49Sep 18, 25$53.33Sep 22, 25$51.54Sep 24, 25$50.65Sep 26, 25$50.05Sep 30, 25$51.94Oct 2, 25$53.28Oct 6, 25$54.61Oct 8, 25$55.30Oct 10, 25$55.49Oct 14, 25$56.50Oct 16, 25$55.03Oct 21, 25$54.36Oct 23, 25$53.81Oct 27, 25$63.56Oct 29, 25$66.62Oct 31, 25$62.64Nov 4, 25$61.37Nov 6, 25$62.73Nov 10, 25$62.81Nov 12, 25$66.22Nov 14, 25$66.39Nov 18, 25$65.59Nov 20, 25$64.62Nov 25, 25$70.63Nov 28, 25$72.01Dec 2, 25$71.46Dec 4, 25$74.76Dec 8, 25$74.24Dec 10, 25$72.70Dec 12, 25$75.15Dec 16, 25$75.69Dec 18, 25$74.14Dec 22, 25$77.09Dec 24, 25$76.53Dec 29, 25$75.61Jan 2, 26$78.24Jan 6, 26$73.99Jan 8, 26$73.82Jan 12, 26$76.84Jan 14, 26$77.90Jan 16, 26$76.26Jan 21, 26$78.15Jan 23, 26$77.87Jan 27, 26$77.87Jan 29, 26$79.10Feb 2, 26$78.24Feb 4, 26$75.19Feb 9, 26$72.29Feb 11, 26$73.33Feb 13, 26$75.25Feb 18, 26$73.93Feb 20, 26$68.14Feb 24, 26$68.31Feb 26, 26$67.61Mar 2, 26$65.50Mar 4, 26$66.54Mar 6, 26$65.36Mar 10, 26$74.32Mar 12, 26$67.98Mar 17, 26$70.94Mar 19, 26$70.07Mar 23, 26$69.60Mar 25, 26$71.61Mar 27, 26$69.70Mar 31, 26$74.26Apr 2, 26$73.15Apr 7, 26$71.93Apr 9, 26$75.52Apr 13, 26$77.87Apr 15, 26$77.70Apr 17, 26$76.75Apr 22, 26$74.44Apr 24, 26$73.28Apr 28, 26$69.71Apr 30, 26$71.11May 4, 26$68.99May 6, 26$68.09May 8, 26$67.39May 12, 26$65.95May 14, 26$69.66May 18, 26$65.32May 20, 26$68.22May 22, 26$69.12May 28, 26$68.45Jun 1, 26$65.36Jun 3, 26$65.48Jun 5, 26$67.61Jun 9, 26$67.68Jun 11, 26$67.55Jun 15, 26$68.00Jun 17, 26$67.39Jun 22, 26$68.92Jun 24, 26$69.36Jun 26, 26$70.24Jul 2, 26$77.19
$43.1952-week range$79.91
Loading valuation history…

Fundamentals

Key fundamentals

$13.2B

Market cap

126.3%

Revenue growth (YoY)

94.4%

Gross margin

-$447M

Free cash flow (USD)

$2.1B

Net debt

6.0%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$40.6MFY 2020$8.2MFY 2021$69.7MFY 2022$77.6MFY 2023$9.3MFY 2024$221.9MFY 2025$502.1M
$0$502.1M

Free cash flow by year

2017 → 2025

FY 2017$-41.0MFY 2018$-154.8MFY 2019$-258.7MFY 2020$-407.2MFY 2021$-546.2MFY 2022$-425.8MFY 2023$-529.0MFY 2024$-521.7MFY 2025$-447.0M
-$41M-$447M

Gross margin by year

2021 → 2025

FY 202195.5%FY 202295.6%FY 202373.7%FY 202498.3%FY 202594.4%
95.5%94.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

10

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventInvestment AgreementJul 2, 2026Filing
  • 8-K eventStock Option Plan UpdateJun 26, 2026Filing
  • Insider sellInsider Sell $342K · 10b5-1 PlanValantine Hannah · Director · $341.5KJun 24, 2026Filing
  • Insider sellInsider Sell $2.8M · 10b5-1 PlanCook Jennifer E. · Director · $2.8MJun 24, 2026Filing
  • Insider sellInsider Sell $6.0M · 10b5-1 PlanCook Jennifer E. · Director · $6MJun 17, 2026Filing
  • Insider sellInsider Sell $5.4M · 10b5-1 PlanKumar Neil · Director, Chief Executive Officer · $5.4MJun 8, 2026Filing
  • 8-K eventFDA Acceptance and Priority ReviewMay 27, 2026Filing
  • Insider sellInsider Sell $1.8M · 10b5-1 PlanKumar Neil · Director, Chief Executive Officer · $1.8MMay 26, 2026Filing
  • Insider sellInsider Sell $671K · 10b5-1 PlanScott Randal W. · Director · $671.5KMay 19, 2026Filing
  • Insider sellInsider Sell $888K · 10b5-1 PlanTrimarchi Thomas · President and CFO · $888.4KMay 19, 2026Filing

Questions

Frequently asked questions

What is BridgeBio Pharma, Inc.'s market cap?

BridgeBio Pharma, Inc. (BBIO) has a market capitalization of $13.2B.

What is BBIO's P/E ratio?

A meaningful P/E ratio is not available for BBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying BBIO stock?

SEC Form 4 filings show no open-market insider buys at BridgeBio Pharma, Inc. in the last 90 days (10 sells).

Same arena

Related companies in Biotechnology

EXEL

Exelixis, Inc.

$12.9B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

ASND

Ascendis Pharma A/S

$13.7B

AXSM

Axsome Therapeutics, Inc.

$12B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.